Janux Therapeutics, Inc. - COMMON STOCK (JANX)

Q1 2023 13F Holders as of 31 Mar 2023

Type / Class
Equity / COMMON STOCK
Shares outstanding
60,558,345
Total 13F shares
30,541,873
Share change
+1,586,917
Total reported value
$369,527,635
Put/Call ratio
4%
Price per share
$12.10
Number of holders
48
Value change
+$18,630,246
Number of buys
30
Number of sells
20

Institutional Holders of Janux Therapeutics, Inc. - COMMON STOCK (JANX) as of Q1 2023

As of 31 Mar 2023, Janux Therapeutics, Inc. - COMMON STOCK (JANX) was held by 48 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 30,541,873 shares. The largest 10 holders included RA CAPITAL MANAGEMENT, L.P., FMR LLC, EcoR1 Capital, LLC, ORBIMED ADVISORS LLC, JANUS HENDERSON GROUP PLC, CITADEL ADVISORS LLC, BVF INC/IL, BlackRock Inc., ADAGE CAPITAL PARTNERS GP, L.L.C., and VANGUARD GROUP INC. This page lists 48 institutional shareholders reporting positions in this security for the Q1 2023 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.